<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
<head>
<title>8 Antibiotics - cell membrane disrupters</title>
<meta http-equiv="Content-Type" content="text/html; charset=iso-8859-1">
		<link href="../sgStyles2.css" rel="stylesheet" type="text/css">
		<csimport user="../../../pharmTox.data/InDesignPackages/8 antibiotics/story_597.incd" occur="0">
			
		</csimport>
	</head>

<body>
<a id="top"></a>
	<div id="text">
		<div id="sumbox">
		
			<div id="drugbox">
			<strong>commonly used drugs</strong><br>
						none
			</div>
		</div>

		<p class="titleSG">Antibiotics causing disruption of the cell membrane</p>
		
		<input type="Button" value="Previous Page" onClick="history.go(-1)">
		
		<csobj csref="../../../pharmTox.data/InDesignPackages/8 antibiotics/story_597.incd" h="834" occur="0" t="Component" g="incopy_default" s="">
			<p class="ParBodytext"><span style="font-weight: bold; ">Polymixin B</span> is a clinically useful member of the polymixin family of simple polypeptide antibiotics produced by <span style="font-style: italic; ">Bacillus polymyxa</span>. <span style="font-weight: bold; ">Colistin</span> is a synonym for Polymixin E, when supplied as a sulphomethyl derivative.</p>
			<p class="ParBodytext"></p>
			<p class="ParBodytext">Polymixins act as cationic detergents (ie, antiseptics - see also skin pharmacology notes) which interact with the phospholipid bacterial cell membrane causing disruption. As a result, the cytoplasm leaks out and the cell dies immediately. Part of their beneficial action may be through binding of bacterial endotoxins which are also phospholipids. They are included here rather than under disinfectants only because they are produced by micro-organisms.</p>
			<p class="ParBodytext"></p>
			<p class="ParBodytext">Polymixin B and colistin produce a rapid kill in most Gram negative bacteria excluding <span style="font-style: italic; ">Proteus </span>spp. Active growth of the organism is not required. Polymixins are particularly useful in treatment of otitis externa and superficial ocular infections caused by <span style="font-style: italic; ">Pseudomonas aeruginosa</span>. Acquired resistance is rare. There is complete cross resistance between polymixin B and colistin.</p>
			<p class="ParBodytext"></p>
			<p class="ParBodytext">These drugs do not discriminate well between microbial and mammalian cell membranes (ie, they are typical disinfectants / antiseptics). They are concentrated in the renal tubule after systemic administration causing acute renal tubular injury. They are also neurotoxic and cause a non-competitive neuromuscular blockade. Use should thus be restricted to topical applications, although they have been used systemically in the hope that they will mop up endotoxins in equine colic.</p>
			<p class="ParBodytext"></p>
			<p class="ParBodytext">Because the molecules are highly charged, no significant absorption occurs after oral or topical administration, even if administered in high doses to inflamed skin.</p>
			<p class="ParBodytext"></p>
			<p class="ParBodytext">Polymixins are highly bound by other drugs, such as tetracyclines, chloramphenicol, sulphonamides and carbenicillin. <span style="font-weight: bold; ">Do not mix them with other drugs</span> (except if commercially prepared). They are inactivated by divalent cations.</p>
			<p class="ParBodytext"></p>
			<p class="ParBodytext">1 mg polymixin B = 8,500 iu, 1 mg colistin = 30,000 iu.</p>
			<p class="ParBodytext"></p>
			<p class="ParSubhead2">The future?</p>
			<p class="ParBodytext">Neutrophils use a family of polypeptides called protegrins (among other things) to kill bacteria. These are being tried out for topical use in people. A synthetic animal derived protegrin, pexiganin, shows promise. No resistance so far. Iseganin is in phase 3 trials in people with cystic fibrosis. It has a broad spectrum and no resistance has been reported so far.</p>
		</csobj>

		
		<table width="90%" border="0" align="center">
			<tr>
				<td class="titleSG"><a href="abIndex.html" class="aTitle">8 Antibiotics index</a></td>
			</tr>
		</table>
		<br>
		<table width="90%" border="0" align="center">
			<tr align="center">
				<td><a href="../../indexpharm.html"><img src="../../PharmBut.gif" width="100" height="21" border="0"></a></td>
				<td><a href="../../toxSite/indexTox.html"><img src="../../ToxBut.gif" width="100" height="21" border="0"></a></td>
				<td><a href="../indexSG.html"><img src="../../SGbut.gif" width="100" height="21" border="0"></a></td>
				<td><a href="../../lectureSite/indexLec.html"><img src="../../LecBut.gif" width="100" height="21" border="0"></a></td>
				<td><a href="../../formSite/Aform.html" target="_blank"><img src="../../FormBut.gif" width="100" height="21" border="0"></a></td>
				<td><a href="../../casesSite/indexCases.html"><img src="../../CaseBut.gif" width="100" height="21" border="0"></a></td>
			</tr>
		</table>
		<br>
		<table width="90%" border="0" align="center" cellpadding="2" cellspacing="0">
			<tr bgcolor="#FFFFFF">
				<td width="50%" class="commonname"><img src="../../pharmBits/images/mulogo.gif" width="170" height="25"></td>
				<td width="50%" align="right" class="references">
					<div align="right">
						copyright
        Massey University</div>
				</td>
			</tr>
		</table>
		<p>&nbsp;</p>
				<div id="gototop"><a href="#top"><b>top</b></a></div>

		</div>
	</body>
</html>
